Nurix Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2019 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Nurix Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2019 to Q4 2024.
  • Nurix Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending November 30, 2024 was $227M, a 17.2% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2024 $227M +$33.3M +17.2% Nov 30, 2024 10-K 2025-01-28
Q4 2023 $194M +$55.4M +40% Nov 30, 2023 10-K 2025-01-28
Q4 2022 $138M +$54.8M +65.7% Nov 30, 2022 10-K 2024-02-15
Q4 2021 $83.5M +$36.1M +76.2% Nov 30, 2021 10-K 2023-02-09
Q4 2020 $47.4M +$7.65M +19.2% Nov 30, 2020 10-K 2022-01-28
Q4 2019 $39.8M Nov 30, 2019 10-K 2021-02-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.